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Introduction
Platelets play a primary role in haemostasis following vas-
cular damage. The major mediators of platelet responses
interact with receptors which converge on activation of the
serine/threonine kinase protein kinase C and increases in
intracellular Ca2þ levels. Solublemediators such as thrombin
signal through receptors coupled to heterotrimeric G pro-
teins, whereas the glycoproteins (GPs) GPVI and CLEC-2
signal through Src family kinases (SFKs) and Syk.1–3 All
pathways lead to covalent modiﬁcation of target proteins
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Abstract Platelet activators stimulate post-translational modiﬁcation of signalling proteins to
change their activity or their molecular interactions leading to signal propagation. One
covalent modiﬁcation is attachment of the small protein ubiquitin to lysine residues in
target proteins. Modiﬁcation by ubiquitin can either target proteins for degradation by
the proteasome or act as a scaffold for other proteins. Pharmacological inhibition of
deubiquitylases or the proteasome inhibition of platelet activation by collagen,
demonstrating a role for ubiquitylation, but relatively few substrates for ubiquitin
have been identiﬁed and the molecular basis of inhibition is not established. Here, we
report the ubiquitome of human platelets and changes in ubiquitylated proteins
following stimulation by collagen-related peptide (CRP-XL). Using platelets from six
individuals over three independent experiments, we identiﬁed 1,634 ubiquitylated
peptides derived from 691 proteins, revealing extensive ubiquitylation in resting
platelets. Note that 925 of these peptides show an increase of more than twofold
following stimulation with CRP-XL. Multiple sites of ubiquitylation were identiﬁed on
several proteins including Syk, ﬁlamin and integrin heterodimer sub-units. This work
reveals extensive protein ubiquitylation during activation of human platelets and opens
the possibility of novel therapeutic interventions targeting the ubiquitin machinery.
 These authors contributed equally to this study.
 B.M.K. and C.J.P. are joint corresponding authors.
received
June 4, 2018
accepted after revision
October 10, 2018
DOI https://doi.org/
10.1055/s-0038-1676344.
ISSN 0340-6245.
© 2019 Georg Thieme Verlag KG
Stuttgart · New York
Cellular Haemostasis and Platelets
THIEME
104
to cause changes in activity or associationwith other cellular
components. The best studied of these modiﬁcations is
phosphorylation, but it is apparent that other modiﬁcations
play an important role in modulating platelet responses.
One modiﬁcation of increasing interest is protein ubiqui-
tylation which is vital to a wide range of cellular responses.4
Ubiquitin is a 76 amino acid residue protein that is ligated to
lysine residues (K) in target proteins. Ubiquitin itself contains
sevenKs towhich further ubiquitinmolecules canbe ligated to
generate a diversity of polyubiquitin chains with different
structures, as well as linear polymers of ubiquitin.5 Modiﬁca-
tion is a three-step reaction. E1-mediated activation of ubi-
quitin is followed by conjugation of ubiquitin to an E2 enzyme.
This is then targeted directly or indirectly via an E3 ligase to a
target substrate. A variety of E1, E2 and E3 enzymes have been
described as well as deubiquitylating enzymes. Ubiquitin
chains are recognized by proteins with ubiquitin binding
domains that are speciﬁc for particular linkages. These pro-
teins can target the modiﬁed protein for degradation by the
proteasome or lead to complex formation to propagate a
signalling response. Classically, K48-polyubiquitin targets pro-
teins to the proteasome for degradation.6 Other linkages such
asK63-linkedubiquitin chains andmono-ubiquitin are impor-
tant in signalling and receptor trafﬁcking.7
A role for the proteasome in platelet functional responses
has been suggested as the proteasome inhibitor bortezomib,
used in the clinic for the treatment of multiple myeloma and
mantle cell lymphoma, inhibits platelet activation by throm-
bin, adenosine diphosphate (ADP) and collagen.8–10 Protea-
some inhibitors block thrombus formation in a mouse FeCl3
model. Pre-treatment of platelets with inhibitors of deubi-
quitylases also block platelet aggregation in response to
these agonists.11 In addition, there is evidence that ubiquitin
is involved in signalling via production of scaffolds. The
tyrosine kinase Syk is ubiquitylated on activation of GPVI
in human platelets.12,13 Ubiquitylation requires activity of
SFKs, and ubiquitylated Syk has increased kinase activity.12
The ubiquitin ligase c-Cbl binds to Syk phosphorylated on
Tyr317.14 Mice deﬁcient in c-Cbl do not show ubiquitylation
of Syk, consistent with c-Cbl being the responsible E3 ligase.
Platelets from c-Cbl-deﬁcient mice show hyper-phosphory-
lation of signalling proteins and increased responses to GPVI
agonists suggesting that ubiquitin modiﬁcation promotes
down-regulation of Syk and ubiquitylation plays an impor-
tant role in platelet functional responses.12,13 It has been
proposed that ubiquitylation of Syk promotes binding of the
tyrosine phosphatase TULA-2 leading to down-regulation of
signalling by Syk. Loss of TULA-2 promotes Syk hyper-phos-
phorylation and platelet hyperactivation.15–17
Proteomic approaches have been applied to human plate-
lets to characterize the complete proteome as well as sub-
sets of proteins that are secreted, phosphorylated or shed
(reviewed in Refs. 18,19, and 20–22). Complete proteome
analysis identiﬁed several other proteins involved in ubiqui-
tin metabolism in human platelets including E1, E2, E3
ubiquitin ligases, deubiquitylases and proteins with ubiqui-
tin binding domains, suggesting a more general role for
ubiquitin in platelet biology.21 For example, the E3 ligase
RNF181 associateswith the intracellular domain of themajor
platelet integrin αIIbβ3.23 Further, several other proteins
have been shown to be ubiquitylated in platelets including
ﬁlamin and talin.10
In this study, we have mapped sites of ubiquitylation of
proteins in resting platelets and following stimulation of GPVI
with collagen-related peptide (CRP-XL). Cleavage of proteins
with trypsin leaves a characteristic tag of two glycine residues
ligated to lysinesmodiﬁed by ubiquitylation. Antibodies direc-
ted against this diGly-tag were used to enrich for tagged
peptides. Mass spectrometry (MS) reveals 1,634 peptides
containing diGly-tags derived from 691 proteins. Of these,
1,116 tagged peptides from 476 proteins were detected in
resting platelets, consistent with widespread protein ubiqui-
tylation. Importantly, marked changes in the ubiquitylation
state (both increases and decreases) are seen in response to
GPVI activation.Note that 905diGly-taggedpeptides showeda
change ofmore than twofold, including numerous sites in Syk,
talin and ﬁlamin, as well as in other proteins known to be
involved inplatelet functional responses.Ouranalysispoints to
a general role for ubiquitylation in platelet regulation. An
understanding of the platelet ubiquitome and its changes
will identify novel targets for therapeutic intervention.
Materials and Methods
Materials
FK2 antibody was purchased from Enzo Life Sciences; anti-
bodies against actin, PLCγ2 and Syk (N19 and 4D10) from
Santa Cruz; LAT, SLP-76 from Millipore; PKCδ and PE-Cy5
anti-CD62P from BD Biosciences; phospho-speciﬁc antibo-
dies for Syk (Y525/526, Y348, Y323) from Cell Signaling; and
ﬂuorescein isothiocyanate (FITC)-conjugated anti-ﬁbrino-
gen antibody was from Agilent Technologies. PR619 and
GST-Tandem Ubiquitin Binding Entities (GST-TUBEs) were
from Tebu-Bio Ltd, and Protein A-Sepharose (PAS) and
NuPage gradient gels from Invitrogen. Other reagents were
from Sigma (Poole, United Kingdom).
Preparation of Human Washed Platelets
Studies on human platelets were performed with ethical
approval from the Oxfordshire Research Ethics Committee
(Ref:08/HO605/123). Blood was drawn from aspirin-free,
healthy consenting volunteers. Whole blood was drawn
into one-tenth total volume sodium citrate and twice-
washed platelets were prepared as previously described.13
For the proteomic analysis, an additional centrifugation step
was introduced to remove leukocytes; platelet-rich plasma
was diluted in 1:1 ratio with modiﬁed Tyrode’s Hepes buffer
(138 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 3 mM NaH2PO4,
5 mM glucose, 10 mM HEPES), pH 7.3 and centrifuged at
240  g for 10 minutes as described.21 Pelleted platelets
were re-suspended in modiﬁed Tyrode’s Hepes buffer, con-
taining 0.2 U/mL apyrase and 10 µM indomethacin, adjusted
to 5  108 platelets/mL (for immunoprecipitation and blo-
tting) or 1.5  109 platelets/mL (for proteomics) and left to
rest for 1 hour at 37°C. Platelets were pre-incubated for
5 minutes in the presence of dimethyl sulfoxide (0.1% v/v),
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PR619 or MG132. Aggregation and dense granule secretion
were monitored as previously described.24
Fluorescence-Activated Cell Sorting Measurement of
Fibrinogen Binding and P-Selectin Exposure
Measurements of ﬁbrinogen binding and P-selectin expo-
sure were performed using washed platelets pre-treated
with or without PR619 (10 µM) and stimulated with CRP-
XL (3 µg/mL) in the presence of FITC-conjugated polyclonal
rabbit anti-ﬁbrinogen antibody and PE-Cy5-conjugated
mouse anti-CD62P antibody, and then incubated for 20
minutes in the dark. Platelets were then ﬁxed by addition
of ﬁltered formyl saline (0.2% formaldehyde in 0.15 M NaCl)
and median ﬂuorescence intensities were measured for
5,000 events in the platelet gate (determined by forward
and side scatter proﬁles) per sample on an Accuri C6 Flow
Cytometer (BD Biosciences, United Kingdom) using the
CFlow Sampler software.
DiGly Pull-Down for Mass Spectrometry
Platelets were prepared from 300 mL of blood from three
donors (100 mL per donor) for each experiment and left
untreated or stimulated with CRP-XL (10 μg/mL) for 5
minutes at 37°C. A total of six different donors were used
over the three experiments: (Experiment 1: Donors A, B, C:
Experiment 2: Donors C, D, E: Experiment 3: Donors A, D, F).
Reactions were stopped by addition of 2 NP40 lysis buffer
(0.5% NP40, 50 mM Tris, pH 7.4, 150 mM NaCl, 20 mM
MgCl2, 2 mM N-ethylmaleimide). Lysates were used for
GlyGly immunoprecipitation using PTMScan Ubiquitin Rem-
nant Motif Kit (Cell Signaling), according to manufacturer’s
protocol. Brieﬂy, extracts were solubilized and denatured in
10 mL lysis buffer (20 mM HEPES, pH 8.0, 9 M urea, 1 mM
sodium orthovanadate, 2.5 mM sodium pyrophosphate,
1 mM β-glycerophosphate), reduced using dithiothreitol
(4.5 mM ﬁnal) for 30 minutes at 55°C. These are conditions
known to cause carbamylation but this will not inﬂuence the
existing covalent diGly modiﬁcations and the mass of carba-
mylation (þ43 Da) is distinguishable from the diGly adduct
(þ114.1 Da). This was followed by alkylation using iodoace-
tamide (100 mM ﬁnal) for 15 minutes at room temperature
in the dark. Possible artefacts due to over-alkylation by
iodoacetamide, which can be misinterpreted as a diGly
modiﬁcation,25 are not observed when the alkylation step
is performed at room temperature.26,27 Samples were sub-
sequently diluted fourfold in 20 mM HEPES, pH 8.0 (2 M
urea ﬁnal), followed by digestion with trypsin-TPCK
(Worthington, LS003744, 10 mg/mL ﬁnal) overnight at 37°
C. Samples were then acidiﬁed using triﬂuoroacetic acid (1%
ﬁnal), and desalted using C-18 Sep-Pak (Waters) cartridges
according to the manufacturer’s protocol. Peptides were
lyophilized and re-suspended in 1.4 mL immunoprecipita-
tion IAP buffer (PTMScan), and the remaining insoluble
material cleared by centrifugation and anti-GlyGly antibody
beads added followed by rotation and kept 4°C overnight.
Beads were subsequently washed twice using 1 mL IAP
buffer, followed by threewater washes. Immunoprecipitated
material was eluted twice in 55 and 50 μL 0.15% triﬂuor-
oacetic acid in water. Eluates were pooled and precipitated
using chloroform and methanol.28 Peptide material was re-
suspended in 20 μL water with 0.1% triﬂuoroacetic acid,
followed by stage-tip desalting and concentration.29 Peptide
eluate material was dried by vacuum centrifugation, and
stored at –80°C.
Mass Spectrometry and Data Analysis
Immunoprecipitated peptide material was re-suspended in
20 μLwaterwith 0.1% triﬂuoroacetic acid and 2% acetonitrile.
Samples were injected into a nano-UPLC U3000 system
(ThermoFisher) coupled to an Orbitrap Fusion Lumos tan-
dem mass spectrometer (MS/MS) (ThermoFisher) as
described previously.30 Peptide material from TUBE pull-
down experiments was analysed using a Waters nano-UPLC
Acquity system coupled to an Orbitrap Velos mass spectro-
meter (ThermoFisher) as described previously.31
MS raw data were processed using the ProteoWizard soft-
ware (Msconvert) and subsequentlyanalysedusing theMascot
(Matrixscience) search engine (v2.5.1) using the UniProt
human protein databases (retrieved June 2011 and October
2014) for searches. Alternatively, for label-free quantitative
analysis, MS raw data were processed using Progenesis QI for
proteomics (QIP) software (v3.0; Nonlinear Dynamics, New-
castle-upon-Tyne, United Kingdom). MS/MS spectra were
searched against the UniProt human sequences (retrieved
October 2014) using Mascot. Precursor mass tolerance was
set to 10 ppm and the fragment ion tolerance to 0.05 Da.
Deamidation on asparagine and glutamine, diGly adducts on
lysine/cysteine, carbamidomethylation on cysteine andoxida-
tion on methionine residues were included as variable mod-
iﬁcations. Peptide false discovery rate (FDR) was set to 1%, and
all peptideswith an ionscoreofgreater than20were imported
into Progenesis QIP. Proteins that were deﬁned with at least
one unique peptide were included in the protein dataset for
further analysis. For normalization, protein abundance values
were centred on themedian abundance of the 90% of proteins
with the lowest variance across all runs. Processed data were
analysed and visualized using the Venny 2.1 and Perseus
software tools (v1.6.0.2). For the analysis by volcano plot, we
used Student’s t-test for the comparison of stimulated versus
unstimulated conditions, which was corrected for multiple
testing using permutation FDR as previously described.32 The
MS data have been deposited to the ProteomeXchange Con-
sortium via the PRIDE partner repository with the dataset
identiﬁer PXD009072 and 10.6019/PXD009072.33
Immunoprecipitation and Pull-Down of Ubiquitylated
Protein
Reactions were stopped by addition of an equal volume of
coldNP40 lysis buffer (150 mMNaCl, 25 mMTris [pH 7.6], 1%
NP-40, 2 mM ethylenediaminetetraacetic acid, 1 mM ethy-
lene glycol tetraacetic acid, 1 mM sodium orthovanadate,
100 μM4-(2-aminoethyl)-benzenesulfonyl ﬂuoride, 1 μg/mL
pepstatin and 10 μg/mL leupeptin). Following incubation on
ice for 15 minutes to ensure lysis, lysates were pre-cleared
using PAS beads. Proteins were immunoprecipitated over-
night at 4°C with 5 μg of appropriate antibodies plus PAS
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(25 μL/500 μL lysate). Syk was immunoprecipitated using
BR15 (kind gift of M. Tomlinson, DNAX Research Institute,
Palo Alto, California, United States). Immunoprecipitates
were washed ﬁve times with lysis buffer and beads boiled
in 2 sodium dodecyl sulphate Laemmli buffer. GST-TUBEs34
were used as per the manufacturer’s instructions. Brieﬂy,
GST-TUBEs were added to platelet lysates for 15 minutes on
ice. Lysates were then clariﬁed by centrifugation at
10,000  g for 10 minutes, before being subjected to stan-
dard to glutathione agarose afﬁnity puriﬁcation. Bound
proteins were eluted using reduced glutathione.
Results
Ubiquitylation of Platelet Proteins
Western blot using an antibody (FK2) that recognizes both
mono- and poly-ubiquitin revealed the ubiquitylation of
multiple proteins in resting human platelets (►Fig. 1A).
The absence of prominent bands is consistent with ubiqui-
tylation of many proteins and/or a range of ubiquitylation
states. The level of total protein ubiquitylation appeared to
increase only modestly on stimulation by CRP-XL. However,
consistent with previous reports using collagen,8 CRP-XL-
dependent platelet aggregation and dense granule secretion
are inhibited in a dose-dependent manner by proteasome
inhibitors MG132 (►Fig. 1B) and bortezomib (data not
shown) suggesting an important role for ubiquitylation
and the proteasome downstream of GPVI. In addition, CRP-
XL-induced aggregation and secretion of both dense and α
granules are inhibited by the pan-deubiquitylase inhibitor
PR619 (►Fig. 1C, D), consistent with previous reports using
collagen.11 PR619 also inhibits CRP-XL-induced activation of
the ﬁbrinogen binding by the major platelet integrin αIIbβ3
(►Fig. 1E), consistent with inhibition of the GPVI signalling
pathway upstream of integrin activation. Inhibition of plate-
let activation by low concentrations of both proteasome and
deubiquitylase inhibitors, at concentrations which do not
inhibit platelet activation by other agonists such as throm-
bin8,10,11 (and data not shown), suggests a dependence on
removal of ubiquitin from proteins for CRP-XL-induced
platelet activation.
To identify sites of ubiquitylation, proteinswere extracted
from control and CRP-XL (10 μg/mL) stimulated human
platelets, and digested with trypsin to leave a characteristic
diGly-tag on lysines to which ubiquitin has been conjugated
(►Fig. 2A). Peptides containing the diGly-tag were enriched
by immunoprecipitation using an antibody speciﬁc for the
tag and identiﬁed by MS (►Supplementary Table S1, avail-
able in the online version). This analysiswas performed three
times, in each case pooling platelets from three individuals.
In total, platelets from six individuals were included in the
analysis, three of these donating on two occasions (see the
“Methods” section for details).
Considering all peptides before and after CRP-XL stimula-
tion revealed in total 1,634 peptides containing diGly-tags on
lysine residues, derived from 691 proteins. Comparing the
three repeats, 403peptides from207proteinsweredetected in
all three experiments and a further 436 peptides from 157
proteins in two repeats. Therefore, 51% of the peptides were
identiﬁed more than once (►Fig. 2B). This level of variation
between experiments is consistent with previous reports for
sites of ubiquitylation from tissue samples (rather than cell
lines). A similar analysis of mouse liver tissue showed 72% of
siteswerepresent in at least two experiments.35Of note, these
mice were inbred and living in a controlled environment
minimizing variation between individuals. In a recent analysis
of the phosphoproteome of human platelets, 50.6% of phos-
phopeptides identiﬁedwere found in only one experimentout
of three.36 Sites identiﬁed in only one experiment could
represent differences between individuals (inherent or envir-
onmental) or technical variation between experiments, but all
are included in ►Supplementary Table S1 (available in the
online version) for maximal coverage.
In resting platelets, 1,116 diGly-tagged peptides from 476
proteins were detected, some proteins containing a large
number of sites including cytoskeletal proteins ﬁlamin (25
sites), Talin (53) andmyosin-9 (25). Therewas ubiquitylation
of several small G proteins (9 different rabs, rap1b, rac1 and
2, cdc42) and receptors associated with inhibitory signalling
(platelet endothelial cell adhesion molecule-1, junctional
adhesionmolecule-A and endothelial cell–selective adhesion
molecule-1). Sites were also apparent on some proteins
involved in platelet activation such as three sites on the Fc
receptor γ (FcRγ)-chain, which forms a complex with GPVI,
and several proteins involved in Ca2þ signalling such as P2X1
receptor (2 sites), Stim1 (7) and the Ca2þ-transporting
ATPase ATP2C1 (9).
Changes in diGly Peptides following Stimulation of
GPVI
Quantiﬁcation of changes in diGly peptide abundance fol-
lowing CRP-XL stimulation (5 minutes) revealed sites that
increased and decreased while others did not change.
►Supplementary Table S2 (available in the online version)
shows all peptides from►Supplementary Table S1 (available
in the online version) where there is signiﬁcant conﬁdence
(p < 0.05) in abundance changes between technical repli-
cates. ►Supplementary Table S3 (available in the online
version) shows only those with changes of more than two-
fold following CRP-XL stimulation. The overlap seen between
experiments was comparable to that seen for the total
number of sites (►Fig. 2C). Note that 716 diGly-tagged
peptides showed a signiﬁcant increase in abundance of
more than twofold (18 from 11 different proteins were
only seen in stimulated samples, 72 from 43 proteins
increased more than 50-fold and 299 from 191 proteins
more than 10-fold in at least one repeat). Peptides from
components of the GPVI signalling pathway such Syk and the
FcRγ-chain are among the proteins showing large increase in
abundance with high conﬁdence, as apparent on a volcano
plot (►Fig. 2D). Note that 445 peptides did not change by
twofold in at least one repeat. Also, 209 peptides from 142
proteins reduced signiﬁcantly by more than twofold (5 were
not detected following stimulation), with 46 peptides from
36 proteins reduced by more than 10-fold, and 9 from 9
proteins by more than 50-fold in at least one repeat.
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Fig. 1 Proteinubiquitylation in restinghumanplatelets andonactivationofglycoprotein (GP)VI. (A)Humanplateletswereallowed to rest before stimulation
with 3 μg/mL collagen-related peptide (CRP-XL) for the times shown. Whole cell lysates were resolved by sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) and blotted using FK2 antibody that recognizes bothmono- and polyubiquitin. The samples were re-probedwith actin to control
for protein loading. (B, C) Human platelets were stimulated with CRP-XL (3 μg/mL) or collagen (1 μg/mL) in the presence of increasing concentrations of
proteasome inhibitor MG132 (B) or pan deubiquitylase inhibitor PR619 (C). Aggregation and dense granule secretion were monitored as previously
described.24 (D,E) Alphagranule secretionwasmeasuredbydetecting levelsof P-selectin exposure (D) andactivationof the integrinαIIbβ3bydetecting levels
of ﬁbrinogen binding (E) at the platelet surface by ﬂow cytometry using PE/Cy5 anti-human CD62P and ﬂuorescein isothiocyanate (FITC)-labelled anti-
ﬁbrinogenantibody, respectively, inwashedplatelets treatedwith3μg/mLCRP-XL.UsingaBDAccuriC6ﬂowcytometer, 5,000eventswereanalysedusing the
CFlow Sampler software.
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Signalling Proteins
Several proteins from the GPVI signalling pathway contained
diGly-tagged peptides. Immunoprecipitation of Syk followed
by Western blot conﬁrmed an increase in ubiquitylation on
CRP-XL treatment (►Fig. 3A), exacerbated by PR619. Syk has
17 ubiquitylation sites, all increasing on CRP-XL treatment
(►Fig. 3B), consistent with previous reports of extensive
laddering of Syk on GPVI activation.12,13 The sites are scat-
tered throughout the protein including a cluster of three sites
between K361 and K375 in the kinase domain of Syk
(►Fig. 3C). The sites showing the highest increases (K300,
334 and 368), also cluster in this central region. A peptide
with two tags (K368, 375) revealed that individualmolecules
of Syk can be modiﬁed on adjacent sites. The increase in
ubiquitylation of Syk observed in the presence of PR619 was
associated with an increase in phosphorylation on several
tyrosine residues, namely, Y525/526, Y323 and Y345
(►Fig. 3D). Inhibition of the proteasome by MG132 did not
lead to a detectable change in ubiquitylation (►Fig. 3A) or a
change in phosphorylation of these same sites (►Fig. 3D) in
Fig. 2 Analysis of diGly-tagged peptides detected by mass spectrometry in resting human platelets and changes on stimulation with collagen-
related peptide (CRP-XL). (A) Schematic of workﬂow used to identify diGly-tagged peptides from human platelets. Cells were collected, lysed and
lysates reduced and alkylated prior to digestion with trypsin. Alkylation was performed using iodoacetamide at room temperature in the dark to
exclude possible artefacts due to over-alkylation of lysine residues.25–27 Gly-Gly peptides were enriched by immunoprecipitation followed by
desalting, concentration and subjected to label-free quantitative analysis by liquid chromatography–tandemmass spectrometry (LC-MS/MS). (B)
Venn diagrams showing the overlap of both proteins (left panel) and peptides (right panel) containing diGly tags on lysine residues as detected
by mass spectrometry in three independent experiments. (C) Venn diagrams showing overlap of proteins (left panel) and peptides (right panel)
containing diGly tags on lysine residues showing a signiﬁcant change in abundance of at least twofold in three independent experiments. (D)
Volcano plot representation of changes in abundance of diGly peptides following platelet activation, highlighting enhanced ubiquitylation of
Syk, CDC42 kinase, FcRγ-chain and c-Cbl and reduced ubiquitylation of ROCK2.
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Fig. 3 Ubiquitylation of Syk and phospholipase Cγ2 in human platelets following activation of glycoprotein (GP) VI receptor with collagen-
related peptide (CRP-XL). (A) Human platelets were stimulated with CRP-XL (3 μg/mL) in the presence or absence of inhibitors of the proteasome
inhibitor MG132 (10 μM) and the pan-deubiquitylase inhibitor PR619 (50 μM). Syk was immunoprecipitated at the times shown and the resulting
Western blot probed with an antibody to ubiquitin (FK2). Samples were re-probed with anti-Syk as a loading control. (B) The site of the diGly-tag
on lysine residues of peptides derived from Syk that were detected in human platelets are shown along with their fold stimulation in the three
independent experiments. The peptide score as determined using Progenesis, the peptide sequence and site of modiﬁcation are also shown.
(C) Schematic diagram showing the location of the sites of ubiquitylation identiﬁed in the human Syk protein relative to its SH2 and kinase
domains. Sites of ubiquitylation as detected as diGly-tagged lysine residues are shown in blue. Known major phosphorylation sites are shown in
orange (tyrosine) and red (serine). (D) Human platelets were incubated for the times shown with vehicle control or 3 μg/mL CRP-XL following
10 minutes of pre-incubation with vehicle, 10 μM PR619 or 10 μM MG132. Whole cell lysates were analysed by Western blot using antisera
speciﬁc for phosphorylated forms of Syk and total Syk. One representative experiment shown. Data from three independent experiments were
quantiﬁed and the average,  standard error of the mean (SEM) shown for each condition.
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Syk. A second tyrosine kinase, Lyn, shows seven ubiquityla-
tion sites (►Fig. 4A), all increasing on activation, with one
peptide containing two modiﬁcations (K9, 20). The FcRγ-
chain is ubiquitylated on four lysine residues, all increasing
robustly on CRP-XL stimulation. One peptide containing two
modiﬁcations (K80, 83) was detected in all three experi-
ments. In contrast, a single site was detected for the tyrosine
kinases Btk, Fyn and Src and phospholipase C (PLC)γ2
(►Fig. 4A). Western blot of immunoprecipitates of PLCγ2
reveals ubiquitylation which increases on treatment with
CRP-XL and is enhanced by the presence of MG132 and
PR619 (►Fig. 4B). The adaptor proteins LAT1, LAT2 and
Fig. 4 Ubiquitylation sites detected by mass spectrometry in human platelets. (A) Components of the glycoprotein (GP) VI signalling pathway.
The site of the diGly-tag on lysine residues of peptides derived from components of the GPVI signalling pathway that were detected in human
platelets are shown along with their maximum fold stimulation in the three independent experiments. (B) Human platelets were stimulated with
collagen-related peptide (CRP-XL) (3 μg/mL) in the presence or absence of the proteasome inhibitor MG132 (10 μM) and the pan-deubiquitylase
inhibitor PR619 (10 μM). PLCγ2 was immunoprecipitated at the times shown and the resultingWestern blot probed with an antibody to ubiquitin
(FK2). Samples were re-probed with anti-PLCγ2 as a loading control. (C) Integrin sub-units. The site of the diGly-tag on lysine residues of peptides
derived from integrin sub-units that were detected in human platelets are shown along with their maximum fold stimulation in the three
independent experiments. (D) Ubiquitin linkages. The site of the diGly-tag on lysine residues of peptides derived from ubiquitin that were
detected in human platelets are shown along with their maximum fold stimulation in the three independent experiments. The peptide score, the
peptide sequence and site of modiﬁcation are also shown.
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SLAP-2 all have sites which increase. Three sites in c-Cbl are
up-regulated in CRP-XL-stimulated platelets, consistent with
a role in signalling downstream of GPVI. In addition to the
tyrosine kinase-dependent signalling pathway, the TRAF4
component of nicotinamide adenine dinucleotide phosphate
oxidase complex also binds directly to the cytoplasmic tail of
GPVI to regulate redox responses and calmodulin binds
directly to the TRAF4 binding sequence.37 TRAF4 was not
identiﬁed in our analysis but three ubiquitylation sites were
found on calmodulin, which also associates with the GPVI
tail, one of which increased by 14-fold in one experiment
(►Fig. 4A;►Supplementary Tables S1, S2 and S3, available in
the online version).
Other proteins involved in platelet activation also showed
increased ubiquitylation such as pleckstrin (seven sites).
Receptors for other platelet agonists such as the protease-
activated receptor 4 thrombin receptor and the purinergic
receptor P2X1 are targets for ubiquitylation as are integrin
sub-units (►Fig. 4C). Three ubiquitylation sites in the C-
terminal tail of the β3-integrin sub-unit were identiﬁed.
Peptides containing two diGly-tags on adjacent lysines were
apparent revealing simultaneous ubiquitylation on the same
protein. PR619 treatment leads to inhibition of platelet
spreading on glass,11 consistent with a role for ubiquitin
turnover in the regulation of outside-in signalling through
the αIIbβ3 integrin, as well as in CRP-XL-induced integrin
activation (►Fig. 1E).
Ubiquitin Pathway
Several diGly-tagged peptides from ubiquitin were detected,
consistent with platelets containing a range of polyubiquitin
chains with K6, K11, K27, K48 and K63 linkages (►Fig. 4D). An
increase in peptide abundance of more than twofold was
observed for all of these. K48-linkages target proteins to the
proteasome, whereas others, such as K63, have a role in
signalling.4 Some proteasome sub-units (ADRM1, PSMA1,
PSMC1, 3 and 6, PSMD1, 3) also showed ubiquitylation
(►Supplementary Table S1, available in the online version).
Ubiquitylation of ligases can be a sign that they are active and
tags on several E2, E3 ligases and deubiquitinating enzymes are
apparent,with several showing increasesonCRP-XL treatment.
Protein modiﬁcation by ligation of the ubiquitin-related
protein Nedd8 also leads to a diGly-tagged residue following
trypsin cleavage. The only well-characterized targets for
Nedd8 ligation are cullins38 and several cullins are found in
the human platelet proteome.21 We detected diGly-tags on
cullin-2, cullin-5 and cullin-9, as well as the Nedd8 E1 activat-
ing enzyme UBA3, and Nedd8 conjugating enzymes Ubc12
(UBE2M) and UBE2F (►Supplementary Table S1, available in
the online version). DiGly-tags were also detected on Nedd8
itself consistent with at least ﬁve different linkages, three of
which changed by more than twofold on CRP-XL treatment.
Cytoskeleton and Vesicle Trafﬁcking Components
Consistent with a previous report of ubiquitylation of both
talin and ﬁlamin,10 we detected 65 different peptides con-
taining diGly-tags derived from talin, 39 sites changing more
than twofold on stimulation, all but one increasing, and 35
diGly-tagged peptides derived from ﬁlamin, 20 increasing by
at least twofold (►Supplementary Table S1, available in the
online version). MS analysis also revealed extensive ubiqui-
tylation for myosin-9, with 40 diGly-tagged peptides, 30 of
which signiﬁcantly increased following stimulation. Thir-
teenmembers of the Rab family of small G proteins, involved
in vesicle trafﬁcking, and other small G proteins such as Rac1
and Ral1 are also ubiquitylated, some of which have been
implicated in platelet function.39–42 Kinases regulated by
monomeric G proteins also showed altered ubiquitylation:
ROCK2 decreases whereas CDC42 kinase increases
(►Supplementary Table S3 [available in the online version],
►Fig. 2C).
Identiﬁcation of Ubiquitin-Containing Complexes by
TUBEs Enrichment
In a separate analysis, protein complexes containing ubiquitin
were pulled down from CRP-XL-stimulated platelets by incu-
bating extracts with GST-tagged TUBEs or GST alone as a
control. TUBEs contain tandem ubiquitin binding domains
which increase their afﬁnity for ubiquitylated proteins.34 The
resulting eluates were analysed by MS (►Supplementary
Table S4, available in the online version) and the overlap in
proteins between two repeats is shown in►Fig. 5A. Ubiquitin
was present in the samples pulled down by TUBEs, but not in
the absence of TUBEs, verifying enrichment (►Fig. 5B). A total
of 1,076 proteins were identiﬁed in the eluates only in the
presence of TUBEswith thehighest scores forﬁlamin, talin and
myosin-9, consistent with the multiple diGly peptides identi-
ﬁed from these proteins. A total of 815 of these proteins were
not identiﬁed in the absence of TUBEs, and in this control ,the
protein with the highest score was GST itself. Several other
proteins identiﬁed in the diGly immunoprecipitates were also
selectively identiﬁed in theTUBEspull-downs, includingpleck-
strin, protein kinase C, integrin-linked kinase (ILK) and Syk.
Several platelet receptors such as GPIb, GPIX, GPV and GPVI
were present in the TUBEs pull-downs. GST-TUBEs enrichment
followedbyWesternblot analysis conﬁrmed theenrichmentof
several proteins identiﬁed in either the diGly-peptide orTUBEs
MS analysis (►Fig. 5B). In the case of LAT, higher molecular
weight forms were enriched in the bound fraction, consistent
with direct polyubiquitylation.
Discussion
Platelet aggregation and dense granule secretion triggered
by CRP-XL are inhibited by proteasome and pan-deubiqui-
tylase inhibitors, demonstrating a role for ubiquitylation
downstreamof GPVI. This is consistent with previous reports
of activating platelets with collagen, which works through
both GPVI and integrin signalling,8,10,11 and that platelets
from mice deﬁcient in the ubiquitin ligase c-Cbl are hyper-
activated in response to GPVI agonists, correlating with loss
of Syk ubiquitylation,12,13 suggesting a speciﬁc role for
ubiquitylation in the GPVI signalling pathway.
Thiswork identiﬁes a large number of proteinsmodiﬁed by
ubiquitylation in resting human platelets and characterizes
changes on stimulation of the GPVI signalling pathway by
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CRP-XL. Plateletswere analysed in the presence of indometha-
cin and apyrase to prevent any potential changes in ubiquityla-
tion caused by secondary mediators such as adenosine
triphosphate and thromboxane. The direct effect of these
secondary mediators on ubiquitylation is unknown. The deu-
biquitylase inhibitor PR619 also inhibits activation of the
platelet integrin αIIbβ3 as measured by ﬁbrinogen binding,
suggesting it works, at least in part, directly on the GPVI-
induced signalling pathway, upstream of integrin activation.
Fragmentationofproteinswith trypsin and subsequent immu-
noprecipitationwith antisera speciﬁc for the diGly-tag indica-
tive of ubiquitylation reveals extensive ubiquitylation of
proteins in resting platelets and changes, mainly increases
but some decreases, following activation of platelets by CRP-
XL. Increase in abundance of peptides could represent
increased activity of ubiquitin ligases, decreased activity of
deubiquitylases or decreased degradation, whereas a
decreased abundance could indicate activation of deubiquity-
lases, inhibition of ligases or increased degradation. In
an alternative approach, in CRP-XL-stimulated extracts,
Fig. 5 Enrichment of complexes containing ubiquitin from collagen-related peptide (CRP-XL) stimulated human platelets using GST-Tandem
Ubiquitin Binding Entities (GST-TUBEs). (A) Venn diagram showing overlap of proteins identiﬁed by mass spectrometry in TUBE-based pull-down
experiments to enrich for poly-ubiquitylated material in platelets 5 minutes after activation with CRP-XL (3 μg/mL). Proteins were enriched by
glutathione sepharose chromatography following incubation of lysates with GST-TUBEs or GST alone and identiﬁed by mass spectrometry.
(B) Human platelets were stimulated with CRP-XL (3 μg/mL) for 5 minutes in the presence of the proteasome inhibitor MG132 (10 μM) and the
pan-deubiquitylase inhibitor PR619 (10 μM). Whole cell lysates were enriched for ubiquitin by association with GST-TUBEs and enrichment
conﬁrmed by Western blot using FK2 (left panel). Samples were probed using antisera speciﬁc for Syk, LAT, SLP76, PLCγ2 and PKCδ signalling
proteins (right panel).
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complexes containing ubiquitylated proteins were pulled
down using GST-tagged TUBEs and eluted proteins identiﬁed
byMS.Completeoverlapbetween thediGlyandTUBEsdatasets
was not expected as the TUBEs analysis enriches for complexes
containing ubiquitylated proteins but not all complex compo-
nents are ubiquitylated. For example, the TUBEs pull-downs
(R2) but not the diGly peptide immunoprecipitates contained
GPVIwhich formsacomplexwithFcRγ-chainwhich in turnhas
four direct sites of ubiquitylation. Conversely, TUBEs will not
enrich for proteins whose ubiquitin modiﬁcations are masked
by binding proteins in a complex, whereas the diGly immu-
noprecipitation involves freepeptides and soall sites shouldbe
exposed. The combination of complimentary approaches is
presented to generate the most extensive database and the
large numbers of proteins identiﬁed in these analyses conﬁrm
the extensive use of this modiﬁcation in human platelets.
There is widespread ubiquitylation of proteins involved in
the GPVI signalling pathway (►Fig. 6), some on multiple
sites, with simultaneousmodiﬁcation of two closely adjacent
sites on Syk, Lyn and FcRγ chain. The function of multiple
sites of ubiquitylation, such as 17 in Syk, is not known. In B
cells, the aminopeptidase DPP9 cleaves the two N-terminal
amino acids of Syk following activation of the B cell receptor,
thus generating a substrate for the N-end rule degradation
pathway by UBR1/3 E3 ligases, and inhibition of DPP9 leads
to Syk stabilization.43 Platelets also express DPP9,21 so a
similar pathway in operation in platelets could explain the
extensive number of ubiquitylation sites and raises the
possibility of a similar degradation pathway for Lyn. Several
of the ubiquitylation sites lie in the vicinity of known
phosphorylation sites. For Syk, platelet activation by CRP-
XL in the presence of PR619, but not MG132, led to an
increase in tyrosine phosphorylation. This correlates with
increased ubiquitylation and is consistent with previous
reports that enriching for ubiquitylated Syk also enriches
for active Syk phosphorylated on Y525/526.12 In PLCγ2, the
single ubiquitylation site identiﬁed (K862) is close to two
knownphosphorylation sites (T857 and Y858). All three sites
of ubiquitylation in the integrin β3 subunit lie in the C
terminal cytosolic tail which forms a platform for interaction
with downstream signalling proteins including talin, Src, Syk
and ILK (reviewed by Durrant et al44), raising the possibility
that ubiquitylation may inﬂuence these interactions.
Several proteins whose function in platelets is not well
characterized nevertheless show extensive ubiquitylation.
For example, 29 diGly-tagged peptides were identiﬁed from
serumdeprivation-response protein, 12 of which changed on
stimulation. This protein interacts with pleckstrin45 and is
also extensively phosphorylated,36 suggestive of a regulatory
role in platelet function. Interestingly, two sites of ubiqui-
tylation are consistently detected in β amyloid protein. The
precursor of this modulates venous thromboembolism in
mice46 and platelets havebeen hypothesized to be a source of
β amyloid protein in plaques in brains of Alzheimer’s
patients.47 Inhibition of β amyloid degradation has been
implicated in plaque formation,48 so it would be of interest
to know if its ubiquitylation in platelets leads to degradation
and if disruption of this contributes to disease progression.
The extent and diversity of the ubiquitome is comparable
to that of the platelet phosphoproteome analysed following
ADP stimulation,36 and targeting this pathway has the
potential to modulate platelet functional responses. It has
already been demonstrated that small molecules that inhibit
the proteasome or deubiquitylases inhibit functional platelet
activation8–11 and that platelets isolated frommice deﬁcient
in the ubiquitin ligase c-Cbl aremore sensitive to activators of
GPVI than platelets from wild-type mice.12,13 The compre-
hensive mapping of the ubiquitome is a ﬁrst step towards
understanding the complexity and mechanisms of ubiqui-
tylation in platelet biology. An increasing number of reagents
which more speciﬁcally target individual members of the
deubiquitylase or ubiquitin ligase family are being
Fig. 6 Schematic of the ubiquitylation of glycoprotein (GP) VI signalling pathway. The major players in the GPVI signalling pathway and their
ubiquitylation status before and after stimulation.
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developed,49,50 raising the possibility that these could act as
speciﬁc modulators of platelet functional responses.
What is known about this topic?
• Proteasome and deubiquitylation inhibitors block
human platelet aggregation suggesting a critical role
for ubiquitylation in platelet activation.
• Ubiquitylation of the tyrosine kinase Syk is ubiquity-
lated in response to activation of GPVI by collagen and
has been proposed to mediate down-regulation of
platelet activation.
• Talin and ﬁlamin also are ubiquitylated in human
platelets.
What does this paper add?
• Resting platelets contain signiﬁcant levels of ubiqui-
tylated proteins. In this study, we identiﬁed 1,116
ubiquitylated peptides derived from 476 proteins.
• Activation of GPVI leads to extensive remodelling of
the ubiquitome,with 925 ubiquitylated peptides chan-
ging more than twofold. In total, 1,634 ubiquitylated
peptides derived from 691 proteins were detected.
• Syk contains at least 17 sites of ubiquitylation, all
increasing upon activation of GPVI.
• Inhibition of deubiquitylation inhibits GPVI-depen-
dent platelet aggregation and secretion.
• Small molecule reagents which speciﬁcally target
individual members of the deubiquitylase or ubiquitin
ligase have therapeutic potential as speciﬁc modula-
tors of platelet functional responses.
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